Methylation silencing of transforming growth factor-β receptor type II in rat prostate cancers

Cancer Research

Volumn 68, Issue 7, 2008, Pages 2112-2121

  Yamashita, Satoshi ^a   Takahashi, Satoru ^b   McDonell, Nathalie ^a   Watanabe, Naoko ^a   Niwa, Tohru ^a   Hosoya, Kosuke ^a   Tsujino, Yoshimi ^a   Shirai, Tomoyuki ^b   Ushijima, Toshikazu ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2',3 DIMETHYL 4 BIPHENYLAMINE; 5 AZA 2' DEOXYCYTIDINE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CARCINOGENESIS; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DOWN REGULATION; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; RAT;

ADENOCARCINOMA; ANIMALS; AZACITIDINE; CELL LINE, TUMOR; DNA METHYLATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HISTONES; HUMANS; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; RATS; RATS, INBRED F344; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; UP-REGULATION;

EID: 42049093597     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-5282     Document Type: Article

References (45)

1. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007;128:683-92.
2. Ushijima T. Detection and interpretation of altered methylation patterns in cancer cells. Nat Rev Cancer 2005;5:223-31.
3. Ushijima T, Okochi-Takada E. Aberrant methylations in cancer cells: where do they come from? Cancer Sci 2005;96:206-11.
4. Fraga MF, Herranz M, Espada J, et al. A mouse skin multistage carcinogenesis model reflects the aberrant DNA methylation patterns of human tumors. Cancer Res 2004;64:5527-34.
5. Pulling LC, Vuillemenot BR, Hutt JA, Devereux TR, Belinsky SA. Aberrant promoter hypermethylation of the death-associated protein kinase gene is early and frequent in murine lung tumors induced by cigarette smoke and tobacco carcinogens. Cancer Res 2004;64:3844-8.
6. Yu L, Liu C, Vandeusen J, et al. Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia. Nat Genet 2005;37:265-74.
7. Dutta KK, Nishinaka Y, Masutani H, et al. Two distinct mechanisms for loss of thioredoxin-binding protein-2 in oxidative stress-induced renal carcinogenesis. Lab Invest 2005;85:798-807.
8. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
9. Shirai T, Takahashi S, Cui L, et al. Experimental prostate carcinogenesis - rodent models. Mutat Res 2000;462:219-26.
10. Shirai T, Tamano S, Kato T, Iwasaki S, Takahashi S, Ito N. Induction of invasive carcinomas in the accessory sex organs other than the ventral prostate of rats given 3,2′-dimethyl-4-aminobiphenyl and testosterone propionate. Cancer Res 1991;51:1264-9.
11. Nakanishi H, Takeuchi S, Kato K, et al. Establishment and characterization of three androgen-independent, metastatic carcinoma cell lines from 3,2′-dimethyl-4-aminobiphenyl-induced prostatic tumors in F344 rats. Jpn J Cancer Res 1996;87:1218-26.
12. Danielpour D. Functions and regulation of transforming growth factor-β (TGF-β) in the prostate. Eur J Cancer 2005;41:846-57.
13. Martikainen P, Kyprianou N, Isaacs JT. Effect of transforming growth factor-β1 on proliferation and death of rat prostatic cells. Endocrinology 1990;127:2963-8.
14. Williams RH, Stapleton AM, Yang G, et al. Reduced levels of transforming growth factor β receptor type II in human prostate cancer: an immunohistochemical study. Clin Cancer Res 1996;2:635-40.
15. Kim IY, Ahn HJ, Zelner DJ, et al. Loss of expression of transforming growth factor β type I and type II receptors correlates with tumor grade in human prostate cancer tissues. Clin Cancer Res 1996;2:1255-61.
16. Guo Y, Jacobs SC, Kyprianou N. Down-regulation of protein and mRNA expression for transforming growth factor-β (TGF-β1) type I and type II receptors in human prostate cancer. Int J Cancer 1997;71:573-9.
17. Guo Y, Kyprianou N. Restoration of transforming growth factor β signaling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspase-1-mediated apoptosis. Cancer Res 1999;59:1366-71.
18. Tang B, de Castro K, Barnes HE, et al. Loss of responsiveness to transforming growth factor β induces malignant transformation of nontumorigenic rat prostate epithelial cells. Cancer Res 1999;59:4834-42.
19. Wikstrom P, Lindh G, Bergh A, Damber JE. Alterations of transforming growth factor β1 (TGF-β1) and TGFβ receptor expressions with progression in Dunning rat prostatic adenocarcinoma sublines. Urol Res 1999;27:185-93.
20. Shi SR, Cote RJ, Wu L, et al. DNA extraction from archival formalin-fixed, paraffin-embedded tissue sections based on the antigen retrieval principle: heating under the influence of pH. J Histochem Cytochem 2002;50:1005-11.
21. Yamashita S, Tsujino Y, Moriguchi K, Tatematsu M, Ushijima T. Chemical genomic screening for methylation-silenced genes in gastric cancer cell lines using 5-aza-2′-deoxycytidine treatment and oligonucleotide microarray. Cancer Sci 2006;97:64-71.
22. Moriguchi K, Yamashita S, Tsujino Y, Tatematsu M, Ushijima T. Larger numbers of silenced genes in cancer cell lines with increased de novo methylation of scattered CpG sites. Cancer Lett 2007;249:178-87.
23. Niwa T, Yamashita S, Tsukamoto T, et al. Whole-genome analyses of loss of heterozygosity and methylation analysis of four tumor-suppressor genes in N-methyl-N′-nitro-N-nitrosoguanidine-induced rat stomach carcinomas. Cancer Sci 2005;96:409-13.
24. Weisinger G, Gavish M, Mazurika C, Zinder O. Transcription of actin, cyclophilin and glyceraldehyde phosphate dehydrogenase genes: tissue- and treatmentspecificity. Biochim Biophys Acta 1999;1446:225-32.
25. Markowitz S, Wang J, Myeroff L, et al. Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science 1995;268:1336-8.
26. Lee CK, Shibata Y, Rao B, Strahl BD, Lieb JD. Evidence for nucleosome depletion at active regulatory regions genome-wide. Nat Genet 2004;36:900-5.
27. Fatemi M, Pao MM, Jeong S, et al. Footprinting of mammalian promoters: use of a CpG DNA methyltransferase revealing nucleosome positions at a single molecule level. Nucleic Acids Res 2005;33:e176.
28. Chang W, Parra M, Ji C, et al. Transcriptional and post-transcriptional regulation of transforming growth factor β type II receptor expression in osteoblasts. Gene 2002;299:65-77.
29. Osada H, Tatematsu Y, Masuda A, et al. Heterogeneous transforming growth factor (TGF)-β unresponsiveness and loss of TGF-β receptor type II expression caused by histone deacetylation in lung cancer cell lines. Cancer Res 2001;61:8331-9.
30. Bae HW, Geiser AG, Kim DH, et al. Characterization of the promoter region of the human transforming growth factor-β type II receptor gene. J Biol Chem 1995;270:29460-8.
31. Weber M, Hellmann I, Stadler MB, et al. Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat Genet 2007;39:457-66.
32. Li B, Carey M, Workman JL. The role of chromatin during transcription. Cell 2007;128:707-19.
33. McCabe MT, Low JA, Daignault S, Imperiale MJ, Wojno KJ, Day ML. Inhibition of DNA methyltransferase activity prevents tumorigenesis in a mouse model of prostate cancer. Cancer Res 2006;66:385-92.
34. Tu WH, Thomas TZ, Masumori N, et al. The loss of TGF-β signaling promotes prostate cancer metastasis. Neoplasia 2003;5:267-77.
35. Bhowmick NA, Chytil A, Plieth D, et al. TGF-β signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 2004;303:848-51.
36. Zhao H, Shiina H, Greene KL, et al. CpG methylation at promoter site -140 inactivates TGFβ2 receptor gene in prostate cancer. Cancer 2005;104:44-52.
37. Dobosy JR, Roberts JL, Fu VX, Jarrard DF. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia. J Urol 2007;177:822-31.
38. Kim IY, Ahn HJ, Zelner DJ, Park L, Sensibar JA, Lee C. Expression and localization of transforming growth factor-β receptors type I and type II in the rat ventral prostate during regression. Mol Endocrinol 1996;10:107-15.
39. Nishi N, Oya H, Matsumoto K, Nakamura T, Miyanaka H, Wada F. Changes in gene expression of growth factors and their receptors during castration-induced involution and androgen-induced regrowth of rat prostates. Prostate 1996;28:139-52.
40. Gorbenko O, Kuznetsov V, Kukharenko O, et al. Identification of a novel binding partners for tumor suppressor PTEN by a yeast two-hybrid approach. Eksp Onkol 2004;26:15-9.
41. Sainaghi PP, Castello L, Bergamasco L, Galletti M, Bellosta P, Avanzi GC. Gas6 induces proliferation in prostate carcinoma cell lines expressing the Axl receptor. J Cell Physiol 2005;204:36-44.
42. Nestl A, Von Stein OD, Zatloukal K, et al. Gene expression patterns associated with the metastatic phenotype in rodent and human tumors. Cancer Res 2001;61:1569-77.
43. Kuerbitz SJ, Pahys J, Wilson A, Compitello N, Gray TA. Hypermethylation of the imprinted NNAT locus occurs frequently in pediatric acute leukemia. Carcinogenesis 2002;23:559-64.
44. Lodygin D, Epanchintsev A, Menssen A, Diebold J, Hermeking H. Functional epigenomics identifies genes frequently silenced in prostate cancer. Cancer Res 2005;65:4218-27.
45. Yu YP, Paranjpe S, Nelson J, et al. High throughput screening of methylation status of genes in prostate cancer using an oligonucleotide methylation array. Carcinogenesis 2005;26:471-9.